Find your path to Mehdi
Sign up to see every warm intro you have to Mehdi
- Paths you didn't know you had: your email and LinkedIn already hold routes to Mehdi. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Mehdi Shahidi pairs deep hands-on development and regulatory expertise—overseeing first-in-human transitions for 30+ NMEs and global approvals at Boehringer Ingelberg—with active leadership roles, making him an embedded R&D partner.
Invests in
BiotechDigital HealthHealthtechMedical Devices
Investments
Led
Petalion Therapeutics
Board seats
CureVac
Investor
D3 BioOttimo Pharma
Per the firm's website.
Colleagues at Medicxi
Frequently asked questions
- Who is Mehdi Shahidi?
- Mehdi Shahidi pairs deep hands-on development and regulatory expertise—overseeing first-in-human transitions for 30+ NMEs and global approvals at Boehringer Ingelberg—with active leadership roles, making him an embedded R&D partner.
- Where does Mehdi Shahidi work?
- Mehdi Shahidi is Venture Partner at Medicxi.
- What does Mehdi Shahidi invest in?
- Mehdi Shahidi invests in Biotech, Digital Health, Healthtech, Medical Devices.
- What boards does Mehdi Shahidi sit on?
- Mehdi Shahidi holds tracked board seats at CureVac.
- What companies has Mehdi Shahidi invested in?
- Investments tracked here include Petalion Therapeutics, D3 Bio, Ottimo Pharma.
- Does Mehdi Shahidi lead rounds?
- Yes — Mehdi Shahidi has led 1 tracked investment.
About this profile. Compiled from public sources — Medicxi's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights







